Similar expression patterns were confirmed in human cell lines, primary PV and CML patient PBMCs and CD34+ cells, demonstrating that these effects are operational in patients. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.